September 10, 2021 – T-CURE BIOSCIENCE ANNOUNCED PRESENTATIONS AT THREE UPCOMING HEALTHCARE CONFERENCES

Sherman Oaks, CA – September 10, 2021 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the management will present virtually at the following upcoming healthcare conferences:

5^th Annual Cell Gene Therapy World Asia 2021, Singapore

• Gang Zeng, Ph.D., Chief Executive Officer, will present virtually on Wednesday, September 16, 2021, at 11:30 am. (Singapore Time). The title of his presentation is “Targeting Solid Tumors with Novel TCR-T Strategies”

2021 Baird Global Healthcare Conference

• Erika von Euw, Ph.D. Senior Director of Translational Research, and Gang Zeng, Ph.D. will give a presentation on T-Cure Bioscience on Wednesday, September 15, at 3:10 p.m. (EDT).

2021 Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

• Erika von Euw, PhD, and Gang Zeng, Ph.D. will give a presentation on T-Cure Bioscience on Thursday, September 23, at 12:25 pm (EDT).

About T-Cure Bioscience, Inc.

T-Cure Bioscience, Inc. is an innovative immuno-oncology company committed to delivering effective and durable cell therapies for the treatment of cancer. The Company focuses on isolating high avidity TCR that can be used to engineer a patient’s T cells to effectively target and destroy solid tumors. The Company maintains a pipeline of TCR under clinical and pre-clinical development targeting HERV-E, KK-LC-1, NY-ESO-1 and other antigens associated with solid tumors of significant unmet medical needs, including kidney cancer, breast cancer, lung cancer, gastric cancer, ovarian cancer, liver cancer, pancreatic cancer, sarcoma, and glioblastoma. More information is available at www.T-Cure.com.